| Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress |
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, announced financial results for the first quarter 2025 and highlighted recent operational progress. "We continued advancement of azenosertib and made solid progress against our strategic goals in the first quarter. |
globenewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company's common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-01 21:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC |
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously disclosed, the Company aligned with the U.S. Food and Drug Administration (FDA) on the design of DENALI Part 2, which allows for seamless enrollment in the two parts of the trial: Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of approximately 30 patients at each of two dose levels: 400mg QD 5:2 and 300mg QD 5:2 (intermittent daily dosing on a five days on, two days off dosing schedule). |
globenewswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting |
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL. |
globenewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company's common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-01 21:30:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates |
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) |
globenewswire.com |
2025-03-26 18:05:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 |
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) |
globenewswire.com |
2025-03-25 18:40:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer |
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients |
globenewswire.com |
2025-03-15 13:25:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on March 3, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 50,000 shares of the Company's common stock and 25,000 restricted stock units to one newly hired employee. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-03 19:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer |
Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer, to be held on March 14-17 in Seattle, Washington. Oral Presentation Abstract Title: Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG-3066) Presenter: Fiona Simpkins, M.D. |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-01 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / NEW YORK, February 27, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-27 13:45:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-25 18:40:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences |
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2025, 11:50 a.m. |
globenewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company")(NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-23 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company")(NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-21 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-20 01:15:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-18 21:04:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-15 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-11 17:22:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company")(NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-09 12:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Zentalis Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026. |
accessnewswire.com |
2025-02-05 15:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company")(NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-05 15:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ZNTL |
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026. |
accessnewswire.com |
2025-02-04 17:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-04 17:05:00 |
Czytaj oryginał (ang.) |
| ZNTL STOCK ALERT: Levi & Korsinsky Notifies Zentalis Pharmaceuticals, Inc. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026. |
accessnewswire.com |
2025-02-04 09:30:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on February 3, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 35,000 shares of the Company's common stock to one newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-03 19:42:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-02-03 12:35:26 |
Czytaj oryginał (ang.) |
| Did Zentalis Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- ZNTL |
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026. |
accessnewswire.com |
2025-02-03 09:25:00 |
Czytaj oryginał (ang.) |
| ZNTL ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Zentalis Pharmaceuticals, Inc. Shareholders Who Lost Money |
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis Pharmaceuticals, Inc.") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026. |
accessnewswire.com |
2025-02-01 20:01:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL |
NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-01 12:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on January 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 45,000 shares of the Company's common stock to two newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-02 18:53:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Key Management Appointments |
Wendy Chang appointed Chief People Officer; Haibo Wang appointed Chief Business Officer Wendy Chang appointed Chief People Officer; Haibo Wang appointed Chief Business Officer |
globenewswire.com |
2024-12-12 09:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on December 2, 2024, the Compensation Committee of Zentalis' Board of Directors granted the following equity awards: non-qualified stock options to purchase an aggregate of 3,028,800 shares of the Company's common stock to Julie Eastland, who joined the Company as Chief Executive Officer and President, non-qualified stock options to purchase an aggregate of 712,650 shares of the Company's common stock to Dr. Ingmar Bruns, who joined the Company as Chief Medical Officer, and non-qualified stock options to purchase an aggregate of 753,660 shares of the Company's common stock to five newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-02 18:35:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm |
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. |
globenewswire.com |
2024-11-21 15:14:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 79,500 shares of the Company's common stock and 21,000 restricted stock units to three newly hired employees. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-01 21:04:00 |
Czytaj oryginał (ang.) |
| FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc |
FMR LLC (Trades, Portfolio), a prominent investment firm, recently adjusted its holdings in Zentalis Pharmaceuticals Inc (ZNTL, Financial), a clinical-stage biopharmaceutical company. On September 30, 2024, FMR LLC (Trades, Portfolio) reduced its position by 3,600,886 shares, resulting in a new total of 5,075,837 shares. |
gurufocus.com |
2024-10-07 18:03:39 |
Czytaj oryginał (ang.) |
| Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies |
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications. |
zacks.com |
2024-09-17 14:25:35 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm |
NEW YORK , Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders. |
prnewswire.com |
2024-09-17 01:38:00 |
Czytaj oryginał (ang.) |
| FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers |
Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.'s ZNTL azenosertib, the company's novel, selective, and orally bioavailable inhibitor of WEE1. |
benzinga.com |
2024-09-16 13:00:35 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies |
Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024 Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024 |
globenewswire.com |
2024-09-16 11:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 |
Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I (TOP1) inhibitor-based antibody drug conjugates Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I (TOP1) inhibitor-based antibody drug conjugates |
globenewswire.com |
2024-09-09 11:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on September 3, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 16,000 shares of the Company's common stock to 2 newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-09-03 20:40:00 |
Czytaj oryginał (ang.) |
| Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why |
The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock. |
zacks.com |
2024-08-26 17:01:22 |
Czytaj oryginał (ang.) |
| Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL |
NEW YORK--(BUSINESS WIRE)---- $ZNTL #NYTop100--Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ:ZNTL) into potential breaches of fiduciary duty by the Company's Board of Directors (the “Board”). Zentalis, headquartered in San Diego, CA, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways. |
businesswire.com |
2024-08-19 20:55:00 |
Czytaj oryginał (ang.) |
| Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-19 15:00:00 |
Czytaj oryginał (ang.) |
| Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-18 15:00:00 |
Czytaj oryginał (ang.) |
| ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Clients to Contact the Firm! |
NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL. |
accesswire.com |
2024-08-18 14:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-17 15:00:00 |
Czytaj oryginał (ang.) |
| Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-08-16 15:00:00 |
Czytaj oryginał (ang.) |
| ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm Today! |
NEW YORK CITY, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL. |
accesswire.com |
2024-08-16 14:00:00 |
Czytaj oryginał (ang.) |